How much funding has GenEdit raised?

GenEdit has raised $118.5M in total funding, most recently a Series B round.

Who are GenEdit's investors?

GenEdit's investors include Eli Lilly, KTB Network, SK Holdings, Company K Partners, Korea Investment Partners, DAYLI Partners.

Where is GenEdit headquartered?

GenEdit is headquartered in South San Francisco, California, United States.

What industry is GenEdit in?

GenEdit operates in Biotech, Therapeutics, Healthcare.

GenEdit

BreezeBio

South San Francisco, United States · Founded 2016 · $118.5M raised

Biotech

Therapeutics

Healthcare

Headquarters: South San Francisco, California
Employees: 51–200
Founded: 2016
Business Model: B2B

Website: genedit.com
Total Funding: $118.5M
Last Round: $60.0M Series BFeb 2026
Rounds: 4

About

GenEdit (now operating as BreezeBio) is a South San Francisco-based genetic medicine company developing nanoparticle delivery technology for gene therapy and gene editing applications. The company's proprietary NanoGalaxy platform provides a library of non-immunogenic nanoparticles that enable targeted delivery of genetic payloads to specific cells and tissues. GenEdit's lead program focuses on autoimmune disease and has established a multi-year collaboration with Genentech. The company rebranded to BreezeBio in 2026 to reflect its pipeline focus on autoimmune disease, including a Type 1 Diabetes program called BRZ-101.

Summary

GenEdit is a Biotech company based in South San Francisco, United States, founded in 2016. It has raised $118.5M in total across 4 rounds, most recently a $60.0M Series B round in Feb 2026. Investors include Eli Lilly, KTB Network and SK Holdings.